Surgical Management of Thick Primary Cutaneous Melanoma in the US

IF 3.1 2区 医学 Q2 ONCOLOGY Cancer Medicine Pub Date : 2025-02-20 DOI:10.1002/cam4.70578
Arthur W. Cowman, Kristel Lourdault, Douglas Hanes, Jessica Weiss, Sean Nassoiy, Melanie Goldfarb, Richard Essner
{"title":"Surgical Management of Thick Primary Cutaneous Melanoma in the US","authors":"Arthur W. Cowman,&nbsp;Kristel Lourdault,&nbsp;Douglas Hanes,&nbsp;Jessica Weiss,&nbsp;Sean Nassoiy,&nbsp;Melanie Goldfarb,&nbsp;Richard Essner","doi":"10.1002/cam4.70578","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>There remains significant variability in the surgical management of thick melanoma patients with clinically node-negative disease. We evaluated factors influencing overall survival (OS) in these patients, focusing on the surgical management of the primary tumor and nodal basin.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Using the National Cancer Database, we identified 7647 patients diagnosed between 2012 and 2017 with thick melanoma (&gt; 4 mm, T4) and clinically node-negative disease. 4332 patients had complete data and met all inclusion criteria. These patients were stratified into three groups based on nodal assessment: sentinel lymph node biopsy (SLNB), elective lymphadenectomy (ELND), or no nodal evaluation (NNE). OS was compared using Kaplan–Meier analyses and multivariable Cox proportional hazard regression.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In the cohort, 2851 (65.8%) had a SLNB, 799 (18.4%) had an ELND, and 682 (15.7%) had NNE. OS significantly decreased for each millimeter of increasing Breslow thickness. Ulceration, lymphovascular invasion, and tumor-positive SLN (+SLN) were associated with worse OS (all <i>p</i> &lt; 0.001). The size of surgical margins was not significantly associated with OS. Five-year OS of patients with SLNB was 67.1% ± 1.2% compared to 57.9% ± 2.3% with ELND and 46.8% ± 2.5% with NNE (<i>p</i> &lt; 0.001). Among +SLN patients, a complete lymph node dissection (CLND) was performed in 400 (62.3%) but was not associated with improved OS (<i>p</i> = 0.67) when compared to the nodal observation group.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Our results suggest that increasing Breslow thickness and nodal assessment provide important prognostic information regarding OS for thick melanoma patients, which emphasizes the importance of SLNB for staging and confirm the lack of benefit of CLND after +SLN in thick melanoma. The size of surgical margins did not affect OS.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 4","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70578","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70578","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

There remains significant variability in the surgical management of thick melanoma patients with clinically node-negative disease. We evaluated factors influencing overall survival (OS) in these patients, focusing on the surgical management of the primary tumor and nodal basin.

Methods

Using the National Cancer Database, we identified 7647 patients diagnosed between 2012 and 2017 with thick melanoma (> 4 mm, T4) and clinically node-negative disease. 4332 patients had complete data and met all inclusion criteria. These patients were stratified into three groups based on nodal assessment: sentinel lymph node biopsy (SLNB), elective lymphadenectomy (ELND), or no nodal evaluation (NNE). OS was compared using Kaplan–Meier analyses and multivariable Cox proportional hazard regression.

Results

In the cohort, 2851 (65.8%) had a SLNB, 799 (18.4%) had an ELND, and 682 (15.7%) had NNE. OS significantly decreased for each millimeter of increasing Breslow thickness. Ulceration, lymphovascular invasion, and tumor-positive SLN (+SLN) were associated with worse OS (all p < 0.001). The size of surgical margins was not significantly associated with OS. Five-year OS of patients with SLNB was 67.1% ± 1.2% compared to 57.9% ± 2.3% with ELND and 46.8% ± 2.5% with NNE (p < 0.001). Among +SLN patients, a complete lymph node dissection (CLND) was performed in 400 (62.3%) but was not associated with improved OS (p = 0.67) when compared to the nodal observation group.

Conclusion

Our results suggest that increasing Breslow thickness and nodal assessment provide important prognostic information regarding OS for thick melanoma patients, which emphasizes the importance of SLNB for staging and confirm the lack of benefit of CLND after +SLN in thick melanoma. The size of surgical margins did not affect OS.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
美国原发性厚皮肤黑色素瘤的外科治疗
临床淋巴结阴性的厚黑色素瘤患者的手术治疗仍然存在显著的差异。我们评估了影响这些患者总生存期(OS)的因素,重点关注原发肿瘤和结盆的手术治疗。方法使用国家癌症数据库,我们确定了7647例2012年至2017年诊断为厚黑色素瘤(> 4 mm, T4)和临床淋巴结阴性疾病的患者。4332例患者资料完整,符合所有纳入标准。这些患者根据淋巴结评估分为三组:前哨淋巴结活检(SLNB),选择性淋巴结切除术(ELND)或无淋巴结评估(NNE)。采用Kaplan-Meier分析和多变量Cox比例风险回归对OS进行比较。结果在该队列中,2851例(65.8%)患有SLNB, 799例(18.4%)患有ELND, 682例(15.7%)患有NNE。Breslow厚度每增加1毫米,OS显著降低。溃疡、淋巴血管侵袭和肿瘤阳性SLN (+SLN)与较差的OS相关(均p <; 0.001)。手术切缘大小与OS无显著相关。SLNB患者的5年OS为67.1%±1.2%,ELND为57.9%±2.3%,NNE为46.8%±2.5% (p < 0.001)。在+SLN患者中,400例(62.3%)进行了完全淋巴结清扫(CLND),但与淋巴结观察组相比,与改善的OS无关(p = 0.67)。结论增加Breslow厚度和淋巴结评估为厚黑色素瘤患者的OS提供了重要的预后信息,强调了SLNB对分期的重要性,并证实了厚黑色素瘤+SLN后CLND的益处不足。手术切缘大小对OS无影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer Medicine
Cancer Medicine ONCOLOGY-
CiteScore
5.50
自引率
2.50%
发文量
907
审稿时长
19 weeks
期刊介绍: Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.
期刊最新文献
The Mediating Effect of Socioeconomic Status and Persistent Poverty on Racial and Ethnic Disparities in Pediatric Cancer Mortality in the United States. Clinical Outcomes and Prognostic Factors of Stereotactic Radiotherapy for Spinal Metastases With Epidural Spinal Cord Compression Grades 1-2. Identification and Validation of cGAS-STING Pathway-Associated Predictive and Therapeutic Models for Esophageal Squamous Cell Cancer Patients via Artificial Intelligence and Multi-Omics. Palliative Care Admission at End-of-Life in Liver Cancer: A 10 Year Population-Based Study of 3565 Deaths in Australia. Hospitalist Care for Unplanned Oncology Admissions: A Mixed-Method Analysis of Oncology and General Hospitalist Outcomes and Processes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1